These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 19685269

  • 1. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
    Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y, Iwase H.
    Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
    [Abstract] [Full Text] [Related]

  • 2. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y, Kawazoe T, Iwase H.
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [Abstract] [Full Text] [Related]

  • 3. Toremifene: an evaluation of its safety profile.
    Harvey HA, Kimura M, Hajba A.
    Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
    [Abstract] [Full Text] [Related]

  • 4. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
    Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ.
    Cancer; 2010 May 15; 116(10):2307-15. PubMed ID: 20209619
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
    Niikura N, Kimura M, Kobayashi Y, Asahara F, Hayashi K, Shibata S, Shintoku J.
    Gan To Kagaku Ryoho; 2009 Jun 15; 36(6):1013-6. PubMed ID: 19542727
    [Abstract] [Full Text] [Related]

  • 6. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
    Kubota O, Onuki Y, Uchiyama T, Oishi K, Takeda M.
    Gan To Kagaku Ryoho; 2012 May 15; 39(5):753-7. PubMed ID: 22584326
    [Abstract] [Full Text] [Related]

  • 7. Toremifene for breast cancer: a review of 20 years of data.
    Vogel CL, Johnston MA, Capers C, Braccia D.
    Clin Breast Cancer; 2014 Feb 15; 14(1):1-9. PubMed ID: 24439786
    [Abstract] [Full Text] [Related]

  • 8. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Langecker P, Blanchett D.
    J Clin Oncol; 2007 Nov 01; 25(31):4961-6. PubMed ID: 17971594
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer adjuvant endocrine therapy.
    Cigler T, Goss PE.
    Cancer J; 2007 Nov 01; 13(3):148-55. PubMed ID: 17620763
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Köberle D, Thürlimann B.
    Breast; 2005 Dec 01; 14(6):446-51. PubMed ID: 16169728
    [Abstract] [Full Text] [Related]

  • 15. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR, Bartlett JM, Canney P, Verrill M.
    Breast Cancer Res Treat; 2007 Jun 01; 103(2):149-60. PubMed ID: 17039263
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.
    Cancer; 2006 Jun 15; 106(12):2576-82. PubMed ID: 16703595
    [Abstract] [Full Text] [Related]

  • 18. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
    Gershanovich ML, Garin AM, Baltinia D, Kurvet A, Kangas L, Ellmen Iu.
    Vopr Onkol; 1997 Jun 15; 43(6):587-95. PubMed ID: 9479357
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.